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Abstract 
Chemokine receptor-4 (CXCR4) has been reported to be overexpressed in glioblastoma (GBM) 
and to be associated with poor survival. This study investigated the feasibility of non-invasive 
CXCR4-directed imaging with positron emission tomography/computed tomography (PET/CT) 
using the radiolabelled chemokine receptor ligand 68Ga-Pentixafor. 
15 patients with clinical suspicion on primary or recurrent glioblastoma (13 primary, 2 recurrent 
tumors) underwent 68Ga-Pentixafor-PET/CT for assessment of CXCR4 expression prior to 
surgery. O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET/CT images were available in 11/15 cases 
and were compared visually and semi-quantitatively (SUVmax, SUVmean). Tumor-to-background ra-
tios (TBR) were calculated for both PET probes. 68Ga-Pentixafor-PET/CT results were also 
compared to histological CXCR4 expression on neuronavigated surgical samples. 
68Ga-Pentixafor-PET/CT was visually positive in 13/15 cases with SUVmean and SUVmax of 3.0±1.5 
and 3.9±2.0 respectively. Respective values for 18F-FET were 4.4±2.0 (SUVmean) and 5.3±2.3 
(SUVmax). TBR for SUVmean and SUVmax were higher for 68Ga-Pentixafor than for 18F-FET (SUVmean 
154.0±90.7 vs. 4.1±1.3; SUVmax 70.3±44.0 and 3.8±1.2, p<0.01), respectively. Histological analysis 
confirmed CXCR4 expression in tumor areas with high 68Ga-Pentixafor uptake; regions of the 
same tumor without apparent 68Ga-Pentixafor uptake showed no or low receptor expression. 
In this pilot study, 68Ga-Pentixafor retention has been observed in the vast majority of glioblastoma 
lesions and served as readout for non-invasive determination of CXCR4 expression. Given the 
paramount importance of the CXCR4/SDF-1 axis in tumor biology, 68Ga-Pentixafor-PET/CT might 
prove a useful tool for sensitive, non-invasive in-vivo quantification of CXCR4 as well as selection of 
patients who might benefit from CXCR4-directed therapy. 
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Introduction 
Glioblastoma (GBM) is the most common ma-
lignant primary tumor of the central nervous system, 
accounting for 45%–50% of all gliomas with an inci-
dence of about 3-4 per 100.000 inhabitants per year [1]. 
Despite multimodality treatment approaches includ-








temozolomide, 5 year survival is abysmal at 5% [1, 2]. 
Thus, there is still an urgent clinical need for new 
therapeutic targets.  
Chemokine receptor-4 (CXCR4) is a member of 
the G-protein-coupled chemokine receptor family [3]. 
The receptor plays an important role in a variety of 
physiologic processes that rely on the recruitment and 
homing of stem cells, progenitor cells, and immune 
cells [3, 4]. It is thus important in embryogenesis, ne-
oangiogenesis, hematopoiesis, and inflammation. 
CXCR4 is overexpressed in more than 20 human tu-
mor types including ovarian, prostate, esophageal, 
and renal cell carcinoma [5], promoting tumor growth 
and progression, tumor invasiveness, and metastasis 
[6]. In GBM, CXCR4 has also been reported to be 
overexpressed and associated with tumor angiogene-
sis [7] as well as poor patient survival [8, 9]. Moreover, 
in animal xenograft experiments, treatment with a 
CXCR4 antagonist significantly inhibited the tumor-
igenicity and the growth of tumors [10], suggesting 
that CXCR4 may play a critical role in promoting the 
progression of human gliomas. A very recent study 
reported on activation of the ERK and PI3K/AKT 
signalling pathway by CXCL12/CXCR4 and its po-
tential implication for targeted therapy of GBM [11]. 
Hence, the CXCR4/CXCL12 axis represents a highly 
relevant molecular target of cancer biology and offers 
promising new approaches and techniques for tar-
geted cancer therapy [12, 13]. 
Recently, 68Ga-Pentixafor, a radiolabelled cyclic 
pentapeptide with high affinity to CXCR4, excellent 
PET imaging characteristics and favorable human 
dosimetry has been developed [14-16]. 
Proof-of-concept for visualization of 
CXCR4-expression has recently been demonstrated in 
patients with hematologic malignancies [17, 18]. The 
present study aimed at the evaluation of 
68Ga-Pentixafor-PET in patients with glioblastoma. 
Patients and Methods 
68Ga-Pentixafor was administered on a compas-
sionate use base in compliance with §37 of the Decla-
ration of Helsinki and The German Medicinal Prod-
ucts Act, AMG §13 2b and in accordance with the re-
sponsible regulatory body (Regierung von Ober-
franken). The study adhered to the standards estab-
lished in the declaration of Helsinki. All patients gave 
written informed consent to receive CXCR4-PET/CT 
imaging on a compassionate use basis. 
Patients 
From April 2014 to April 2015, a total of 15 pa-
tients (7 males, 8 females, mean age, 61±12 years; 
range, 42-77 y) scheduled for surgical resection or 
biopsy of suspected primary (13/15 pt.) or recurrent 
(2/15 pt.) GBM were enrolled (for details Table 1). 
Both patients with suspected recurrence had previ-
ously undergone surgical resection followed by irra-
diation and concomitant and adjuvant chemotherapy 
with temozolomide. The time from completion of ra-
diation to the PET scan was > 12 weeks in these 2 pa-
tients.  
68Ga-Pentixafor-PET was done within 1-23 days 
prior (mean, 6±6 days) to surgery/ tumor biopsy. 
O-(2-18F-fluoroethyl)-L-tyrosine (18F-FET) PET scans 
for comparison were available in 11/15 subjects. 
Scans were performed at a mean interval of 12±6 days 
(range, 2-36 days) before surgery. The median time 
interval between both PET scans was 1 day (range, 
0-35 days). Standard magnetic resonance imaging 
(MRI) was available in all subjects. 
With surgery/biopsy scheduled in all cases, one 
patient rapidly deteriorated after imaging and was 
therefore unable to undergo tumor resection. In the 
remaining 14 subjects, histopathology served as gold 
standard to verify diagnosis as well as the presence of 
viable tumor tissue. 
Table 1: Patients’ characteristics and imaging results. 
    CXCR4 FET 
Nr Sex Age (y) Disease SUVmean SUVmax TBR SUVmean TBR SUVmax SUVmean SUVmax TBR SUVmean TBR SUVmax 
1 F 60 GBM 6.14 7.34 68.2 35.0 4.55 5.40 3.1 3.1 
2 M 77 GBM 5.07 7.3 253.5 73.0 n/a n/a n/a n/a 
3 F 75 GBM 2.23 2.87 111.5 57.4 4.12 5.07 3.6 3.7 
4 F 64 GBM 3.68 4.48 184.0 89.6 n/a n/a n/a n/a 
5 M 73 GBM 2.41 3.04 241.0 152.0 n/a n/a n/a n/a 
6 M 59 PCNSL 4.02 6.01 201.0 75.1 n/a n/a n/a n/a 
7 M 42 GBM 2.48 2.96 248.0 148.0 5.04 6.48 6.1 5.7 
8 M 64 GBM neg neg n/a n/a 3.12 3.96 3.3 3.1 
9 F 57 Oligo III 0.75 0.89 25.0 12.7 6.15 7.19 4.7 4.3 
10 F 48 Ischemia 2.59 3.3 86.3 27.5 2.64 3.10 1.9 1.7 
11 F 69 GBM 0.95 1.29 95.0 64.5 2.81 3.23 5.5 4.4 
12 F 76 GBM 3.29 4.32 65.8 43.2 9.38 11.62 5.3 5.1 
13 M 42 Astro III neg neg n/a n/a 4.23 5.14 4.8 4.1 
14 F 60 GBM 3.14 4.21 314.0 105.3 2.88 3.36 2.3 2.0 
15 M 50 GBM 2.18 3.02 109.0 30.2 3.12 3.71 4.2 4.1 
In addition to clinical factors, results of both 68Ga-Pentixafor- as well as 18F-FET-PET are given. n/a = not applicable; SUV = standardized uptake value; TBR = tu-
mor-to-background ratio. 




Preparation of 68Ga-Pentixafor and 18F-FET 
Synthesis of 68Ga-Pentixafor was performed by 
means of a fully GMP compliant automated synthe-
sizer (GRP, Scintomics, Germany) [15, 19]. 18F-FET 
was prepared according to the corresponding 
monography in the European Pharmacopoeia as pre-
viously described [20, 21]. 
PET Imaging  
All PET scans were performed on a dedicated 
(PET/CT) scanner (Siemens Biograph mCT 64; Sie-
mens Medical Solutions). For 68Ga-Pentixafor, injected 
activity ranged from 83 to 158 MBq (mean: 130±28 
MBq). Imaging started 60 min after tracer injection. 
18F-FET scans were started 20 min after injection of 
180-229 MBq (mean: 207±14 MBq). 
Low dose CT scans of the brain for attenuation 
correction were acquired (35 mAs, 120 keV, a 512 × 
512 matrix, 5 mm slice thickness, increment of 30 
mm/s, rotation time of 0.5 s, and pitch of 0.8). All PET 
images were reconstructed using corrections for at-
tenuation, dead-time, random events and scatter. The 
PET scanner is periodically checked for calibration 
accuracy as part of quality control according to pub-
lished guidelines [22]. 
Image Analysis 
Images were analyzed as recently described [23]. 
In brief, images were first inspected visually (CL, 
KH). Then the axial PET image slice displaying the 
maximum tumor uptake was selected by drawing a 
3D-volume of interest (VOI) around the whole tumor 
area. Tumor regions of interest (ROIs) were defined in 
2 ways. First, a standardized 10-mm circular region 
was placed over the area with the peak activity. This 
first ROI was used to derive maximum (SUVmax) and 
mean standardized uptake values (SUVmean). A nor-
mal reference brain region was defined by drawing a 
ROI (diameter of 25 mm) involving the entire contra-
lateral hemisphere at the level of the centrum semio-
vale to derive tumor-to-background ratios. Addition-
ally, another ROI (3D isocontour) was placed in the 
superior sagittal sinus (at the tumor level) to derive an 
estimate of blood pool activity. The radiotracer con-
centration in the ROIs was normalized to the injected 
dose per kilogram of patient’s body weight to derive 
the SUVs. 
Neurosurgery 
68Ga-Pentixafor-PET/CT and T1-weighted rapid 
three-dimensional gradient-echo technique 
(MP-RAGE) MR images were transferred to a neu-
ro-navigation system (Stealth Station S7, Medtronic 
Navigation, Louisville, USA) and combined in image 
fusion planning (StealthMerge Image Registration, 
Medtronic Navigation, Louisville, USA). During sur-
gery of the gliomas, neuro-navigated biopsy speci-
mens were obtained from areas with 68Ga-Pentixafor 
uptake by three experienced neurosurgeons (M.L.; 
T.L.; A.F.K). In 5 cases, separate tumor samples with 
high and low/no tracer accumulation were biopsied, 
respectively.  
Histological characterization of tumors  
All tumors were histologically assessed and 
graded on formalin fixed and paraffin embedded tis-
sue sections by an experienced neuropathologist 
(CMM) and pathologist (IK), respectively, according 
to the 2007 criteria of the World Health Organization 
[24] and as previously described [20]. Glial origin of 
the tumor cells was confirmed by the positive reaction 
with gliofilament antiserum GFAP (1:200, Clone 6F2, 
Dako, Hamburg, Germany). To determine the prolif-
erative activity of tumor cells, Ki-67 labeling index 
was calculated after immunostaining for MIB-1 
(monoclonal, clone Ki-67, 1:50, Dako, Hamburg, 
Germany) by determining the number of positive 
nuclei among 100 tumor cells per high power field 
(HPF) (x400) in a total of 10 HPF per sample.  
CXCR4-immunohistochemistry was performed 
and scored as described previously [17] using 3µm 
thick paraffin-slices and an anti-CXCR4 rabbit poly-
clonal antibody (ab2074; Abcam, Cambridge, UK) 
followed by detection with the DAKO en vision sys-
tem according to the manufacturer′s protocol. In brief, 
a so-called immune-reactive score (IRS) was calcu-
lated by multiplying the percentage of CXCR4+ cells x 
the intensity of staining. Score points range from 0-12. 
All immunostained sections were counterstained 
for 2 minutes with hematoxylin in order to identify 
the specific kind of cell (tumoral, parenchymal) ex-
hibiting positive CXCR4 immunostaining.  
Statistical Analysis 
Statistical analyses were performed using PASW 
Statistics software (version 22.0; SPSS, Inc. Chicago, 
IL). Quantitative values were expressed as mean ± 
standard deviation or median and range as appropri-
ate. Comparisons of related metric measurements 
were performed using Wilcoxon-signed rank test. The 
Chi square- or Fisher exact test was conducted for 
comparison of frequency data between independent 
subgroups. For bivariant correlation analyses Spear-
man or Pearson correlation coefficients were calcu-
lated. All statistical tests were performed two-sided 
and a p-value < 0.05 was considered to indicate sta-
tistical significance. No correction for p-values was 
applied to adjust for multiple tests. 






In all patients the brain lesions were located in 
the cerebral hemispheres. 7/15 subjects presented 
with temporal (temporo-occipital) lesions, 6/15 with 
frontal lesions, 1 had a parietal (parieto-occipital) tu-
mor and 1 patient had occipital disease.  
Final diagnosis was established by histopathol-
ogy of surgical or biopsy samples in 14/15 patients. 
Both patients with recurrent disease had GBM with 
secondary GBM evolving from grade III astrocytoma 
in 1 patient (patient #6). The other patient suffered 
from recurrence of previously diagnosed primary 
GBM (patient #8). 
In 8 patients with suspected primary GBM the 
clinical diagnosis was confirmed by histopathology. 
One patient presented with oligodendroglioma III°, 
another with anaplastic astrocytoma III°. In one pa-
tient primary central nervous system lymphoma 
(PCNSL) could be diagnosed, inflammatory changes 
after stroke mimicked GBM in the remaining patient.  
Visual PET Image Analysis 
All patients with suspected primary and recur-
rent high-grade gliomas (with contrast-enhancement 
in T1-weighted MRI) showed enhanced 18F-FET up-
take (11/11), whereas one patient with GBM (patients 
#8) and the single patient with anaplastic astrocytoma 
III° (patient #13) did not display 68Ga-Pentixafor up-
take (detection rate, 13/15). All lesions were clearly 
delineated from normal brain tissue. Of note, highly 
68Ga-pentixafor positive lesions were mainly con-
trast-enhancing. Overall, the two tracers showed a 
matching image pattern upon visual assessment in 
4/11 cases with inter-individual differences in uptake 
intensity without a tracer preference; however, these 
were not of relevance for image interpretation. In 7 
subjects, tracer distribution varied distinctly. One 
example is given in Figure 1.  
Semiquantitative Image Analysis 
SUVmean and SUVmax for 18F-FET were higher 
than those for 68Ga-Pentixafor (4.4±2.0 and 5.3±2.3; 
3.0±1.5 and 3.9±2.0 respectively (p=0.05 and p=0.1)). 
18F-FET and 68Ga-Pentixafor SUVmean and SUVmax 
were not correlated (r= 0.12 and r=0.05; p=ns). 
Background SUVmean and SUVmax were much 
higher for 18F-FET as compared to 68Ga-Pentixafor 
(1.1±0.4 and 1.4±0.5 versus 0.03±0.02 and 0.08±0.05; 
p<0.01). Consistently, TBR for SUVmean and SUVmax 
were higher for 68Ga-Pentixafor than for 18F-FET 
(SUVmean 154.0±90.7 vs. 4.1±1.3; SUVmax 70.3±44.0 and 
3.8±1.2, p<0.01), respectively (Table 1). The patient 
with PCNSL (patient #6) presented with 
68Ga-Pentixafor SUVmean and SUVmax of 4.02 and 6.01, 
respectively (no 18F-FET available). In the subject with 
ischemic infarction (patient #10), both PET scans were 
visually positive. Corresponding 68Ga-Pentixafor 
SUVmean and SUVmax were 2.6 and 3.3 (18F-FET: 2.6 
[SUVmean] and 3.1 [SUVmax], respectively) (Table 1). 
In 68Ga-Pentixafor-PET, blood pool activity 
ranged between 1.2 and 3.2 (median, 1.6; mean, 




Figure 1: Example of dis- and concordant distribution of 68Ga-Pentixafor and 18F-FET in glioblastoma patients. Given are transaxial slices of contrast-enhanced, 
T1-weighted MRI, 68Ga-Pentixafor- and 18F-FET-PET in two patients with glioblastoma. Whereas tracer distribution is concordant in patient #14, marked differences 
can be observed in patient #11. 





In 14/15 patients, imaging results could be 
compared to immunohistological staining for CXCR4. 
2/14 samples were rated “weakly” (both IRS score 2), 
6/14 “moderately” (IRS scores 4-8) and 5/14 
“strongly” (IRS scores 9-12) positive (Table 2). The 
sample of the patient diagnosed with an ischemic 
stroke (patient 10) was rated “negative” (IRS score 0) 
due to the absence of CXCR4+ tumor cells. A high 
degree of CXCR4-expressing macrophages and glial 
cells in this specimen was found to account for the 
positive CXCR4-PET. The two cases with weak 
CXCR4-expression presented with a negative 
68Ga-Pentixafor-PET scan. This apparent discrepancy 
is explained by the low percentage (<2% and 10-20%, 
respectively) of CXCR4-positive tumor cells. Consid-
ering the moderately and strongly positive sections, 
CXCR4 score did not correspond to the intensity of 
68Ga-Pentixafor uptake (SUVmean, SUVmax, TBRmean, 
TBRmax). 
Apart from the tissue samples from CXCR4+ re-
gions, additional neuro-navigated biopsy specimens 
were available from areas with low/no 
68Ga-Pentixafor uptake in another 5 patients (#1, 9, 10, 
11, 12). Interestingly, a negative or low 
68Ga-Pentixafor signal was associated with a negative 
or rather weak CXCR4 expression on tumor cells in all 
cases (Table 2 and Figure 2). 
Immunohistochemical assessment of Ki-67 was 
available in 10/15 patients (Table 2), but was neither 
correlated with PET-derived parameters nor with 
CXCR4 expression (p=ns; Supplementary Figure 1). 
Application of the Spearman’s rho correlation coeffi-
cients resulted for 68Ga-Pentixafor in R=0.354 
(R2=0.125; p=0.316) for both SUVmax and SUVmean. 
Corresponding values for IRS were R=0.332 (R2=0.11; 
p=0.348). In 2 cases, the level of Ki-67 expression 
could be compared in 68Ga-Pentixafor positive vs. 
negative sections: while the proliferative index of the 
CXCR4- section was lower than that of the CXCR4+ 
one in patient #9 (5% vs. 15%), it did not differ in the 
other patient (#11; 5% for both). 
 
Table 2: Immunohistochemical assessment of surgical samples for 
CXCR4 expression and Ki-67 compared to 68Ga-Pentixafor-PET. 
Nr CXCR4 
SUVmean 





1 6.14 CXCR4+ 6 2 5% 
  CXCR4- 0 0 n/a 
2 5.07 CXCR4+ 9 3 20% 
3 2.23 n/a n/a n/a n/a 
4 3.68 CXCR4+ 6 2 20% 
5 2.41 CXCR4+ 6 2 10% 
6 4.02 CXCR4+ 12 3 >80% 
7 2.48 CXCR4+ 4 2 10% 
8  CXCR4- 2 1 2% 
9 0.75 CXCR4+ 9 3 15% 
  CXCR4- 4 2 5% 
10 2.59 CXCR4+ 0 0 25% 
  CXCR4- 0 0 n/a 
11 0.95 CXCR4+ 9 3 5% 
  CXCR4- 2 1 5% 
12 3.29 CXCR4+ 12 3 40% 
  CXCR4- 2 1 n/a 
13 neg CXCR4- 2 1 15% 
14 3.14 CXCR4+ 6 2 30% 
15 2.18 CXCR4+ 6 2 n/a 
Immunohistochemical assessment of CXCR4+ and CXCR4- tumor samples (as 
assessed by 68Ga-Pentixafor-PET) in comparison to 68Ga-Pentixafor-PET results 
(CXCR4-SUVmean) and Ki-67 labelling index. For histological graduation, a so-called 
immunoreactive score was calculated by multiplying the percentage of CXCR4+ 
cells x the intensity of staining. Score points range from 0-12. For classification, the 
following system was used: 0-1 = 0 (negative); 2-3 = 1 (weak expression); 4-8 = 2 






Figure 2: CXCR4 Expression in CXCR4+ and CXCR4- tumor samples (as assessed by 68Ga-Pentixafor-PET). Exemplary depiction of immunohistochemical staining 
for CXCR4 in biopsies from both 68Ga-Pentixafor negative (red dotted line; positive in 18F-FET-PET) and positive (green) tumor areas, respectively (patient #1). 
68Ga-Pentixafor-PET/CT and T1-weighted rapid three-dimensional gradient-echo technique (MP-RAGE) MR images were transferred to a neuronavigation system for 
specific sampling. Nuclei are stained with H&E. Magnification: 200x. 
 





The CXCR4/CXCL12 axis plays a fundamental 
role in the biology of various tumor entities. In glio-
mas, CXCR4 mRNA and protein expression has been 
shown to be connected to higher tumor grading [25], 
earlier recurrence [7] and shorter survival [25]. In our 
study, we could demonstrate for the first time that 
non-invasive imaging of CXCR4 in human malignant 
glioma using 68Ga-Pentixafor is feasible. In 11/13 pa-
tients with high-grade glioma, 68Ga-Pentixafor-PET 
yielded positive results and receptor expression of 
malignant cells could be confirmed by immunhisto-
chemical work-up. Whereas 68Ga-Pentixafor uptake 
was not higher or even lower than amino acid 
transport, -due to the extremely low background ac-
tivity in 68Ga-Pentixafor-PET- tumor-to-background 
ratios were very favorable and significantly higher 
than for 18F-FET. Of note, tumor samples from areas 
without apparent tracer accumulation demonstrated 
absent or only low CXCR4-expression, thus confirm-
ing specificity of the radiopharmaceutical.  
Due to its critical role for proliferation and 
spread of malignant gliomas, CXCR4 is an attractive 
target for new treatment approaches. Recently, a 
therapeutic vector for CXCR4 has been developed by 
Wester and co-workers [14, 15, 26] and successfully 
applied in a proof-of-concept study in advanced stage 
myeloma patients [27]. Given that CXCR4-directed 
therapy alone [28] or in combination with te-
mozolomide [29] has already yielded promising re-
sults, endoradiotherapy with radiolabelled 
CXCR4-ligands seems a promising new approach for 
glioblastoma therapy. In this scenario, the main ap-
plication of 68Ga-Pentixafor would not primarily be 
tumor delineation but identification of potential can-
didates for targeted therapy. CXCR4-directed 
PET/CT should be performed as a first non-invasive 
tool to select imaging-positive patients as potential 
candidates. As reports have hinted at a particularly 
high receptor expression in cancer stem cells [30], an-
ti-CXCR4 treatment strategies might be even more 
effective than conventional approaches. 
Interestingly, in our cohort both inflammatory 
changes after brain ischemia as well as primary CNS 
lymphoma presented with 68Ga-Pentixafor uptake. 
This was accounted for by CXCR4+ macrophages and 
lymphoma cells, respectively, which both have been 
demonstrated to overexpress CXCR4 on the cell sur-
face as well [18, 31]. Though a certain influence of 
non-tumoral cells on the Pentixafor-signal in GBM 
cannot be excluded, physiologically abundant micro-
glial cells as well as lymphocytes do not generate a 
relevant 68Ga-Pentixafor signal as can be deducted 
from the extremely low background values in our 
cohort. This finding further underlines the versatility 
of this new tracer in a broad spectrum of pathologies 
ranging from inflammatory diseases such as auto-
immune diseases, cardiac regeneration after acute 
myocardial infarction and recovery after cerebral 
stroke to tumorigenesis, cancer cell proliferation and 
metastasis in more than 30 different tumor entities.  
Our results are in line with a recently published 
study on the feasibility of non-invasive visualization 
of CXCR4 expression using PET with another 
68Ga-labelled imaging agent [32]. In 8 patients with 
suspected high-grade glioma, the authors could also 
demonstrate the specific binding of their tracer to the 
chemokine receptor on the cell membrane. Interest-
ingly, in our cohort the patients with gliomas WHO 
III° showed rather low (patient #9, anaplastic oli-
godendroglioma III°) or no (patient #13, anaplastic 
astrocytoma III°) 68Ga-Pentixafor-uptake. Whereas 
immunohistochemistry corroborated negative imag-
ing findings in one patient (#13), the remaining 
Pentixafor-negative patient presented with a high 
histological receptor expression. The reason for this 
discordant observation is not fully understood yet, 
but might be influenced by receptor kinetics and in-
ternalization, given that CXCR4 expression at the cell 
surface is dynamically regulated and receptor inter-
nalization is induced by ligand binding. The biologi-
cal implications of this finding need to be further in-
vestigated on in future larger series. In contrast to a 
published study investigating neuroendocrine neo-
plasms [33], we could not demonstrate a correlation 
between Ki-67 and CXCR4 expression in our cohort, 
though some cases with low Ki-67 expression also 
demonstrated low Pentixafor uptake (e.g. patients #7, 
#9, and #11). This observation should also be con-
firmed in larger series.  
Our study has several limitations. First, only a 
limited number of patients could be included, though 
it is larger than the series reported with 
68Ga-NOTA-NFB before [32]. Staining for stem cell 
markers such as CD133 to confirm the theory with 
particularly high receptor expression on the cell sur-
face of glioblastoma stem cells was not performed, 
thereby heterogeneity of CXCR4 in GBM cannot be 
addressed. Future studies comparing radiotracer 
binding with histologic CXCR4 expression need to be 
conducted. 68Ga-Pentixafor uptake did not correlate 
with histological receptor expression, maybe due to 
receptor kinetics and internalization. However, since 
imaging-negative patients proved to be 
CXCR4-negative in immunostaining, 68Ga-Pentixafor 
might serve as readout to identify or exclude potential 
candidates for CXCR4-directed therapy.  
This pilot study is the first report to demonstrate 
the feasibility of non-invasive imaging of CXCR4 with 




68Ga-Pentixafor, a tracer that has already been 
demonstrated to exhibit excellent imaging character-
istics in lymphoproliferative diseases. Given the need 
for new effective treatment alternatives in GBM, en-
doradiotherapy with 90Y- or 177Lu-labelled, 
68Ga-Pentixafor-derived vectors might be a new op-
tion for glioblastoma patients. Further research inves-
tigating the underlying mechanistic and biologic im-
plications is therefore highly warranted. 
Conclusion 
In this pilot study, 68Ga-Pentixafor retention has 
been observed in the vast majority of glioblastoma 
lesions and served as readout for non-invasive visu-
alization of intracerebral CXCR4 expression. Given 
the paramount importance of the CXCR4/SDF-1 axis 
in tumor biology, 68Ga-Pentixafor-PET/CT might 
prove a useful (theranostic) tool for sensitive, 
non-invasive in-vivo quantification of CXCR4 (tumor 
phenotyping), and, potentially, prognostication and 
selection of patients who might benefit from 
CXCR4-directed therapy. 
Supplementary Material  
Supplementary Figure 1. 
http://www.thno.org/v06p0428s1.pdf 
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